News 2023-06-23
Porton Pharma Solutions Expands Global Reach with New Site in Slovenia and Enhanced Manufacturing Capabilities
Porton Pharma Solutions Ltd. continues to expand its reach globally. Last year, we launched the construction of a new site in Menges, Slovenia. The state-of-the-art GMP manufacturing site will significantly expand Porton’s network beyond China and the US as it sets out to provide solutions to customers and partners in Europe.
Moreover, Porton also started production in its Drug Product cdmo and cell and gene therapy CDMO commercialization facilities. It also began implementing the APS (Advanced Planning and Scheduling) to boost the efficiency in production scheduling and order fulfillment and promote transparency in capacity planning management.
All these production and operation efforts are part of Porton’s commitment to providing high-quality services.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
